At 19.4% CAGR, South & Central America Malaria Treatment Market is Projected to be Worth US$ 247.33 Million by 2030, says Business Market Insights

According to Business Market Insights' research, the South & Central America malaria treatment market was valued at US$ 59.68 million in 2022 and is expected to reach US$ 247.33 million by 2030, registering a CAGR of 19.4% from 2022 to 2030. Extending pipeline of new drugs and vaccines and growing strategic initiatives are among the critical factors attributed to the South & Central America malaria treatment market expansion.

Antimicrobial resistance can put the public at risk of many diseases, such as malaria. To overcome this challenge, the R&D of new medicines is considered the best strategy; as a result, the antimalarial pipeline is becoming increasingly robust. Public-private partnerships are accelerating research activities related to the treatment of malaria. For instance, Medicines for Malaria Venture (MMV), a nonprofit organization, works with numerous pharmaceutical companies to reduce the burden of malaria by developing novel treatment options. Therefore, the growing number of antimalarial and drugs/vaccines that are under clinical development are expected to boost the market growth in the future.

A few antimalarial that are under clinical development are mentioned in the table below:

Table 1.    Malaria Drugs/Vaccine/Compounds Under Clinical Development

Drug    Developer    Clinical Trial Stage

Artefenomel    Sanofi     Phase IIb

KAE609     Novartis AG    Phase IIb

KAF156    Novartis AG    Phase IIb

DSM265    Takeda Pharmaceutical Company    Phase IIa

SANARIA PfSPZ-GA1    Sanaria    Phase II

SANARIA PfSPZ Vaccine - Radiation Attenuated PfSPZ Vaccine    Sanaria    Phase II

SANARIA PfSPZ-CVac    Sanaria    Phase II

MSP3-CRM-Vac4All    Vac4All    Phase I

Liver-Stage Antigen-3 (LSA3)    Vac4All    Phase IIa

Source: Company Website, Business Market Insights Analysis

Therefore, the growing number of antimalarial and drugs/vaccines that are under clinical development are expected to boost the market growth in the future.

On the contrary, availability of counterfeit antimalarial drugs followed by subsequent drug resistance hurdles the growth of South & Central America malaria treatment market.

Based on treatment, the South & Central America malaria treatment market is categorized into generic drugs, originators, vaccines, and others. The vaccines segment held 95.0% share of South & Central America malaria treatment market in 2022, amassing US$ 56.70 million. It is projected to garner US$ 236.77 million by 2030 to expand at 19.6% CAGR during 2022-2030.

In terms of route of administration, the South & Central America malaria treatment market is bifurcated into oral and parenteral. The oral segment held 69.7% share of South & Central America malaria treatment market in 2022, amassing US$ 41.57 million. It is projected to garner US$ 169.90 million by 2030 to expand at 19.2% CAGR during 2022-2030.

By distribution channel, the South & Central America malaria treatment market is categorized into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment held 45.5% share of South & Central America malaria treatment market in 2022, amassing US$ 27.17 million. It is projected to garner US$ 113.01 million by 2030 to expand at 19.5% CAGR during 2022-2030.

Based on country, the South & Central America malaria treatment market has been categorized into Brazil, Argentina, and the Rest of South & Central America. Our regional analysis states that Brazil captured 86.4% share of South & Central America malaria treatment market in 2022. It was assessed at US$ 51.58 million in 2022 and is likely to hit US$ 214.78 million by 2030, exhibiting a CAGR of 19.5% during 2022-2030.

Key players operating in the South & Central America malaria treatment market are Cipla Ltd, Sun Pharmaceutical Industries Ltd, Sanofi SA, GSK Plc, Novartis AG, Pfizer Inc, and Lupin Ltd, among others.

•    In November 2022, Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria.
  
  
•    In October 2021, GSK welcomes WHO recommendation for broad roll-out of its RTS,S/AS01e (RTS,S) malaria vaccine.
  
  

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com